16 results
6-K
MREO
Mereo Biopharma Group Plc
28 Apr 20
Current report (foreign)
4:10pm
; or
Supply chain interruptions.
TheCOVID-19 pandemic continues to rapidly evolve and the extent to which it may impact our future business is highly
6-K
EX-99.2
MREO
Mereo Biopharma Group Plc
2 Nov 21
Current report (foreign)
4:16pm
required for the Company’s ongoing development activities;
Supply chain interruptions; or
Diversion of CMO activities and raw materials to COVID-19
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
setrusumab, alvelestat, etigilimab, acumapimod and leflutrozole; building our intellectual property portfolio; developing our supply chain; planning our … by the current or anticipated impact of supply chain disruptions, labor shortages, fluctuations in currency exchange rates, changes in interest rates, trade
F-3/A
yautgwtb7
27 Sep 21
Shelf registration (foreign) (amended)
4:18pm
F-3/A
0qbev1j
7 Sep 21
Shelf registration (foreign) (amended)
4:06pm
F-3
2tfairkqi3dksmi51
5 Aug 21
Shelf registration (foreign)
4:33pm
424B3
i8r ahpbgdr77d
20 Mar 19
Prospectus supplement
4:58pm
F-4/A
fr0 yrzlpmszm
15 Mar 19
Registration of securities (foreign) (amended)
5:08pm
F-4
ybfak hp55oih
25 Jan 19
Registration of securities (foreign)
12:00am
F-1/A
bqdp02ejwmx9
6 Mar 20
Registration statement (foreign) (amended)
5:32pm
20-F
dd1pddx7xkn20y5h4l
29 Apr 19
Annual report (foreign)
4:59pm
F-1/A
het2wfd8um 6pf1hjxib
12 Mar 20
Registration statement (foreign) (amended)
5:15pm
- Prev
- 1
- Next